Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 7/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16700695 | 1.00 | MKNK1 (0.56) | MKNK1EGFRTBK1SYKBTK | |
| SCHEMBL16700236 | 0.90 | MKNK1 (0.60) | MKNK1EGFRABL1 | |
| SCHEMBL16700232 | 0.90 | MKNK1 (0.60) | MKNK1EGFRABL1 | |
| SCHEMBL16705866 | 0.90 | MKNK1 (0.60) | MKNK1EGFRABL1 | |
| SCHEMBL16700518 | 0.86 | MKNK1 (0.60) | MKNK1EGFRSYK | |
| SCHEMBL16700519 | 0.86 | MKNK1 (0.60) | MKNK1EGFRSYK | |
| SCHEMBL16705856 | 0.85 | MKNK1 (0.56) | MKNK1EGFRTBK1SYKJAK3 | |
| SCHEMBL16701085 | 0.85 | MKNK1 (0.56) | MKNK1EGFRTBK1SYKJAK3 | |
| SCHEMBL16701084 | 0.85 | MKNK1 (0.56) | MKNK1EGFRTBK1SYKJAK3 | |
| SCHEMBL16699853 | 0.85 | MKNK1 (0.59) | MKNK1EGFRTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | Bayer Pharma AG (DE) | 2015-05-14 | — | — | US | claimed |
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | Bayer Pharma AG (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | Bayer Pharma AG (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | Bayer Pharma AG (DE) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | DPYD, VEGFA, FLT1 | MKNK1 2315/4885EGFR 1218/4885TBK1 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.